HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patientsMUNICH, Germany, June 20, 2023 (GLOBE NEWSWIRE)...